Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
PR Newswire
Report Store
UsernamePublicRestriction
Tags:
Financing Research & Development Clinical Trials

Dante Labs Invests In UK To Apply Consumer Genome Sequencing To COVID-19 Variants

  • News

Executive Summary

The L'Aquila, Italy-based company announced a £30m investment in global surveillance of new variants of the SARS-CoV-2 virus.

You may also be interested in...



Exec Chat: Adaptive Biotechnologies Will Use T Cells To Spot Prior Infections, Including COVID-19

Adaptive chief medical officer Lance Baldo talked to Medtech Insight about the company's plans to detect prior infection using T-cells obtained from blood samples.

Digital Health Roundup, January/February 2021: The Continued Rise Of AI, Telehealth

In this new roundup feature focusing on the most notable developments in digital health, we pick the key news from the year so far. 

Sensyne Algorithm For COVID-19 Risk Prediction Gets UK Regulatory Approval

Sensyne obtained UK regulatory approval for its SYNE-COV machine learning algorithm to assess the long-term risks of COVID-19.

Table

View full table

Topics

Tags:
Financing Research & Development Clinical Trials
UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By